A-192621 is a potent, non-peptide, orally active, and selective endothelin B (ETB) receptor antagonist used to study ETB receptor-mediated physiological responses; it promotes apoptosis in pulmonary arterial smooth muscle cells (PASMCs), enhances cellular susceptibility to doxorubicin-induced apoptosis, elevates arterial blood pressure, and increases plasma ET-1 levels in vivo.